Mauna Kea Technologies Investor Relations Material

Mauna Kea Technologies SA is a French medical device company that specializes in developing and marketing advanced optical biopsy systems. The company's flagship product, Cellvizio, is a probe-based Confocal Laser Endomicroscopy (pCLE) platform. This technology allows physicians to obtain real-time, high-resolution cellular images during endoscopic procedures, primarily for detecting abnormalities in the gastrointestinal and pulmonary tracts, particularly in cancer patients. The Cellvizio system is designed to improve diagnostic accuracy and support more immediate treatment decisions, with applications across multiple medical specialties. Mauna Kea Technologies is headquartered in Paris, France, and its shares are listed on the Euronext Paris.